1 published article · Updated continuously
5 trials tracked for Upper respiratory tract infection: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 1 citation.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Carbocisteine cough syrup has been shown to significantly reduce cough scores in patients with upper respiratory tract infections. Specifically, treatment resulted in a significant reduction in the Night Cough Score from the first night of treatment (p<0.01) and at the end of the study period (p<0.01). Additionally, a statistically significant decrease in Day Cough Scores was observed by the end of the study (p<0.05) 2.
Clinical data exists regarding the administration of a combination of paracetamol (500 mg), dimethindene maleate (1 mg), and phenylephrine hydrochloride (10 mg) for symptom management, with recorded daily averages for total symptoms reaching 169.2 and 225.3 3.
The Novavax COVID-19 vaccine (2023-2024 formula XBB containing) has been evaluated in a Phase 4 study involving 1,188 participants 1.
AI synthesis of 3 cited trials, updated Aug 3, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
